GLP-1 Agonists and Hair Loss: What the Semaglutide and Tirzepatide Trial Data Actually Shows

A client sits down in the chair and tells you she’s been shedding for three months. She’s not sure why. Her labs are normal. She hasn’t changed shampoo, hasn’t had a baby, hasn’t been sick. The only thing that’s changed is that she’s down thirty pounds since January, and she’s finally happy about how she looks, except for the handfuls of hair in the shower drain. Somewhere in the conversation, usually about ten minutes in, she mentions Ozempic. Or Wegovy. Or Mounjaro. Or Zepbound.

If you work in hair, this conversation is now happening every week. The GLP-1 receptor agonist drugs went from niche diabetes medications to one of the most-prescribed drug classes in the United States in under five years. An estimated 1 in 8 American adults has now used a GLP-1 medication at some point, and that number is climbing. Which means the hair loss signal in the clinical trials, the one that dermatologists and endocrinologists were quietly tracking for the last four years, is now sitting in trichology chairs across the country.

This is what the peer-reviewed evidence actually says about GLP-1 agonists and hair: what the landmark trials found, why the mechanism matters, what the pharmacovigilance data is flagging, and how to manage a client who is on one of these drugs and losing hair. The story is more nuanced than either “it’s just telogen effluvium, don’t worry” or “Ozempic causes hair loss, stop taking it.”

What the Trials Actually Documented

STEP 1 was the pivotal Phase 3 trial that led to the FDA approval of semaglutide 2.4 mg (Wegovy) for chronic weight management. 1,961 adults with overweight or obesity were randomized to once-weekly subcutaneous semaglutide or placebo over 68 weeks alongside lifestyle intervention. Mean weight loss in the semaglutide group was 14.9%, versus 2.4% with placebo. This is the trial that moved GLP-1 therapy from a diabetes indication into mainstream obesity medicine.

Buried in the adverse event table: alopecia occurred in 3.0% of the semaglutide group versus 1.5% of the placebo group. The absolute numbers are small, but the doubling over placebo and the difference reaching the adverse-event-reporting threshold are meaningful. This was the first peer-reviewed trial signal of hair loss on a GLP-1 drug at weight-loss dosing. A subsequent STEP 8 analysis comparing semaglutide 2.4 mg versus liraglutide 3.0 mg in 2022 found alopecia in 3.3% of the semaglutide arm versus 1.5% of liraglutide, suggesting a dose or potency relationship.

SURMOUNT-1 was the tirzepatide equivalent: 2,539 adults with obesity randomized to once-weekly tirzepatide (5, 10, or 15 mg) or placebo over 72 weeks. Mean weight loss at the 15 mg dose was 20.9%, the largest magnitude ever documented in a pharmacologic weight-loss trial. Zepbound (the obesity-indication brand name for tirzepatide) was FDA-approved in late 2023 on the basis of this trial.

Alopecia occurred in 5.7% of patients on tirzepatide 15 mg versus 1.0% on placebo. At the 10 mg dose it was 4.9%. At the 5 mg dose, 4.9%. The dose response is not linear, but the effect size is substantially larger than what STEP 1 showed with semaglutide, and it is almost six-fold over placebo at the highest dose. The investigators did not provide mechanistic analysis in the primary publication. The alopecia was flagged as a non-serious adverse event and did not drive treatment discontinuation in any meaningful way.

One note: the trial-reported alopecia rates almost certainly underestimate the real-world incidence. Clinical trial adverse event reporting depends on spontaneous patient reporting during scheduled visits, and diffuse hair shedding is a symptom most people do not think to mention unless asked directly. Post-marketing surveillance, which we will get to in a moment, tells a somewhat different story.

The Pharmacovigilance Signal

FAERS is the FDA’s post-marketing adverse event database. Signal-detection analyses compare the frequency of a specific adverse event for a target drug versus all other drugs in the database, using statistical metrics like the reporting odds ratio (ROR) and the proportional reporting ratio (PRR). An elevated ROR above prespecified thresholds is considered a disproportionate signal worth investigating.

The 2024 FAERS analyses published in JAMA Dermatology and JAMA Network Open found that alopecia reports for semaglutide were disproportionately elevated, particularly in women. Reports for tirzepatide followed a similar pattern. Importantly, FAERS signals are not proof of causation, but they do mean the clinical trial finding was not a statistical accident. The signal persists in real-world post-marketing data, and at higher apparent rates than the registration trials indicated.

What the FAERS data cannot tell us is mechanism. It flags an association. Whether that association is driven by the drug itself, by the rapid weight loss the drug produces, by the nutritional shifts in people who are eating substantially less, or by some combination of all three, is a separate question, and it is the most clinically important question for practitioners.

The Mechanism Question: Telogen Effluvium, or Something Else

Rapid weight loss is a known trigger of telogen effluvium. This has been documented in the bariatric surgery literature for decades. Post-bariatric telogen effluvium typically begins 3–4 months after the procedure, corresponds to the timing of maximal caloric deficit, affects roughly 40–60% of patients in the first 6–12 months, and resolves spontaneously as weight stabilizes and nutritional status is restored. The mechanism is metabolic: sudden caloric restriction and the associated shifts in protein, iron, and micronutrient availability push a disproportionate number of follicles out of anagen and into telogen, producing a synchronized shedding event 2–4 months later.

On the surface, GLP-1-induced alopecia fits the telogen effluvium pattern cleanly. Semaglutide and tirzepatide produce caloric deficits of 500–1,000 kcal per day in many patients. They reduce protein intake, iron intake, and often total food variety. The shedding onset most clients describe, roughly 2–4 months after dose escalation, is textbook telogen effluvium timing. Trichoscopy at that stage shows increased telogen ratio without perifollicular inflammation or miniaturization. When the medication is stopped or weight stabilizes, regrowth typically follows. This is consistent with a reactive, self-limited process.

But the story may not be purely metabolic. Several observations complicate the pure-TE hypothesis. The tirzepatide alopecia rate is nearly twice the semaglutide rate at comparable weight-loss magnitudes in SURMOUNT versus STEP, which is not what you would predict if the effect were purely proportional to weight loss. GLP-1 receptors have been identified in skin, sebaceous glands, and hair follicle-associated structures in preclinical work, raising the possibility of direct pharmacologic activity on hair cycle regulation. And a subset of reported cases appear to persist or progress beyond the typical 6–12 month TE resolution window, which would be unusual for straightforward nutritionally-driven shedding.

The current best-supported interpretation is that the majority of GLP-1-associated hair loss is telogen effluvium driven by rapid weight loss and the associated nutritional and metabolic stress, with a possible additional contribution from direct receptor-mediated effects that has not yet been definitively characterized. This matters clinically because it determines how you counsel the client.

What the Dermatology Literature Is Saying

The dermatology consensus that has emerged over the past eighteen months positions GLP-1-associated alopecia as primarily a telogen effluvium phenomenon with an unusually high incidence. The recommended framework treats it like any other drug-triggered or stress-triggered TE: confirm the diagnosis with history, hair pull test, and trichoscopy; optimize nutritional status; support the hair cycle during the shedding phase; and set realistic expectations about resolution timing.

The clinical protocol that has coalesced in the literature includes:

Nutritional workup. A full panel including ferritin (target >70 ng/mL for hair), iron, TIBC, vitamin D, B12, zinc, and in female patients, thyroid function and basic hormonal assessment if indicated. GLP-1 patients commonly develop iron deficiency and low ferritin from reduced red meat intake and reduced total dietary variety. Supplementation and dietary counseling are first-line.

Protein assessment. A specific question about protein intake in grams per day, not just general diet quality. Hair shaft production requires substrate. Many GLP-1 patients are eating 30–50 grams of protein per day when they should be eating 80–120. Protein supplementation, ideally in food form but protein shakes if necessary, is a specific intervention with real downstream impact on hair.

Minoxidil, if appropriate. Topical 5% minoxidil or low-dose oral minoxidil has become a common add-on in GLP-1-associated shedding, partly to shorten the telogen phase and pull follicles back into anagen. Evidence specific to GLP-1-induced TE is still emerging, but the extrapolation from other TE causes is reasonable and widely practiced.

Do not reflexively stop the drug. GLP-1 agonists are treating a serious chronic condition for most of the people on them, and the long-term cardiovascular, metabolic, and quality-of-life benefits typically outweigh a self-limited shedding event. The decision to continue, reduce, or discontinue belongs to the prescribing physician and the patient, with dermatology or trichology input on severity. The trichologist’s role is diagnostic clarity and supportive management, not medication management.

Women, Androgens, and the Subset Who Get Hit Harder

The FAERS reports skew female. That is unsurprising given the demographics of GLP-1 use for weight loss. But there is a subset of female patients who appear to experience disproportionate or protracted shedding on these drugs, and an emerging clinical hypothesis is that rapid weight loss in women with underlying androgenetic alopecia susceptibility unmasks or accelerates pattern hair loss that would otherwise have progressed slowly over years.

The mechanism would be straightforward: rapid caloric restriction shifts sex hormone-binding globulin and free testosterone ratios, can disrupt menstrual function, and places a heavier share of the follicle population into telogen. In a woman who has androgen-receptor-sensitive follicles at the vertex and mid-scalp, the shedding event may preferentially drop miniaturized follicles that do not fully recover, producing a step-wise worsening of pattern thinning rather than pure TE.

This is hypothesis, not proven mechanism. But the clinical observation is consistent enough that assessing for signs of pattern hair loss in any female client on a GLP-1 who presents with shedding is now standard. If the trichoscopy shows hair diameter variability or widening of the central part out of proportion to the shed pattern, the picture is no longer pure TE and the management conversation shifts.

Reversibility: What the Follow-Up Data Shows

The reassurance most trichologists give about drug-induced telogen effluvium, it will grow back, is largely supported in the GLP-1 data available so far. In the trial populations, reported alopecia events were almost uniformly non-serious, did not require discontinuation, and resolved with time. Post-marketing case series describe similar resolution patterns in the majority of reported cases, with full or near-full regrowth by 12–18 months after drug stabilization or discontinuation, consistent with standard TE trajectories.

The caveats: in patients with pre-existing pattern hair loss, the regrowth may be incomplete to the extent that the shedding event advanced underlying AGA or FPHL. In patients with protracted caloric deficits or frank malnutrition, the hair cycle may not fully recover until nutritional status normalizes. And the long-term tail of the FAERS data, meaning patients with persistent alopecia more than 18–24 months after drug initiation, remains to be fully characterized in peer-reviewed literature.

What This Means for Your Practice

Ask every new shedding client about GLP-1 medications. Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, Rybelsus. Ask by brand name because patients often do not know the generic name. Include compounded semaglutide and tirzepatide from med spas and online clinics in the question, because those are a huge share of current use and do not always appear on medication lists.

Timing matters for the diagnosis. Shedding that starts 2–4 months after a dose escalation or the start of therapy is classic GLP-1-associated TE. Shedding that precedes the drug, or that is clearly pattern thinning with a different chronology, is a different diagnosis and should not be attributed to the medication.

Ferritin, iron, vitamin D, B12, zinc, and protein intake are the core workup. GLP-1 patients commonly have silent nutritional deficits that matter more for hair than for general health. A full panel is not overkill; it is the standard of care for TE on these drugs.

Trichoscopy distinguishes pure TE from masked pattern loss. Empty telogen follicles without miniaturization point to TE alone. Hair diameter variability, widening of the central part, and frontal thinning on scope point to concurrent FPHL that the GLP-1-driven shedding is unmasking. The management changes.

Do not tell clients to stop their medication. That decision belongs to them and their prescriber. Your job is to clarify the diagnosis, quantify the severity, rule out contributors, support the hair cycle, and communicate to the prescribing physician when the severity warrants a clinical conversation about dose adjustment or alternative therapy.

Set expectations around timing. Clients on GLP-1 drugs are often also losing weight they have wanted to lose for years. The shedding feels like a betrayal. A clear explanation that this is predictable, likely reversible, and has a defined timeline is meaningfully different from vague reassurance and often prevents them from abandoning treatment prematurely.